|drug4644||patients receiving nasal high flow Wiki||1.00|
|drug2902||Physiological saline solution Wiki||1.00|
|D011024||Pneumonia, Viral NIH||0.11|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
There is one clinical trial.
Recombinant human angotensin-converting enzyme 2 (rhACE2) as a treatment for patients with COVID-19 to block viral entry and decrease viral replication.
Description: The primary endpoint is a composite endpoint of all cause-death or invasive mechanical ventilation up to 28 days or hospital dischargeMeasure: All Cause-death or invasive mechanical ventilation Time: 28 days
Description: Log transformed levels of Lactate dehydrogenase (LDH) at day 5 as a surrogate marker for organ damage (powered secondary endpointMeasure: LDH level Time: Day 5
Description: 28-day mortality (all cause-death)Measure: Mortality Time: 28 days
Description: Ventilator-free days (VFD) up to 28 days or hospital dischargeMeasure: VFD Time: 28 days
Description: Time to death (all causes)Measure: Time to death Time: 28 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports